title: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
abstract: OBJECTIVE
  This clinical trial was conducted to evaluate the efficacy and safety of Palonosetron in preventing chemotherapy-induced vomiting (CIV) among the Chinese cancer patients.
  
  
  METHODS
  Two hundred and forty patients were scheduled to be enrolled and randomized to receive a single intravenous dose of palonosetron 0.25 mg, or granisetron 3 mg, 30 min before receiving highly emetogenic chemotherapy. The primary efficacy endpoint was the complete response (CR) rate for acute CIV (during the 0-24-h interval after chemotherapy). Secondary endpoints included the CR rates for delayed CIV (more than 24 h after chemotherapy).
  
  
  RESULTS
  Two hundred and eight patients were accrued and received study medication. CR rates for acute CIV were 82.69% for palonosetron and 72.12% for granisetron, which demonstrated that palonosetron was not inferior to granisetron in preventing acute CIV. Comparisons of CR rates for delayed CIV yielded no statistical difference between palonosetron and granisetron groups and did not reveal non-inferiority of palonosetron to granisetron. Adverse events were mostly mild to moderate, with quite low rates among the two groups.
  
  
  CONCLUSIONS
  A single dose (0.25 mg) of palonosetron is not inferior to a single dose (3 mg) of granisetron in preventing CIV and possesses an acceptable safety profile in the Chinese population.
authors.affiliation: Department of Clinical Oncology, Xijing Hospital, The Fourth Military Medical University, No 15, West Changle Road, Xi'an, 710032, China.
authors.forename: Zhaocai
authors.initials: Z
authors.lastname: Yu
authors.forename: Wenchao
authors.initials: W
authors.lastname: Liu
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.forename: Houjie
authors.initials: H
authors.lastname: Liang
authors.forename: Ying
authors.initials: Y
authors.lastname: Huang
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Si
authors.forename: Helong
authors.initials: H
authors.lastname: Zhang
authors.forename: Duhu
authors.initials: D
authors.lastname: Liu
authors.forename: Hongmei
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D044466:Asian People; D002681:China; D004311:Double-Blind Method; D005260:Female; D017829:Granisetron / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D000077924:Palonosetron; D011812:Quinuclidines / Q000009:adverse effects / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D017829:Granisetron; D007546:Isoquinolines; D000077924:Palonosetron; D011812:Quinuclidines; D012702:Serotonin Antagonists